The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback